Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer.

Mafalda OliveiraLaia GarrigósJuan David AssafSantiago Escriva-de-Romani Cristina Saura

Published in: Expert review of anticancer therapy (2020)

Neratinib plus capecitabine is a valid treatment option for patients with advanced HER2-positive breast cancer, after progression to at least two anti-HER2-based regimens. Given the multiple options that are being developed in this context, efforts should be employed to establish strong predictive biomarkers of efficacy to each drug and combination.

Keyphrases

positive breast cancer
randomized controlled trial
emergency department
clinical trial
radiation therapy
locally advanced
quality improvement
phase iii
drug induced